Randomized Study of Succimer (Dimercaptosuccinic Acid) on Growth of Lead-Poisoned Children
Completed
Nationwide Children's Hospital
N/A
1997-09-01
OBJECTIVES:
Compare growth of lead-poisoned children receiving succimer (dimercaptosuccinic acid; DMSA)
plus standard treatment to those receiving standard treatment only.
Randomized Study of Succimer (Dimercaptosuccinic Acid) on Growth of Lead-Poisoned Children
Completed
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
N/A
1997-09-01
OBJECTIVES:
Compare growth of lead-poisoned children receiving succimer (dimercaptosuccinic acid; DMSA)
plus standard treatment to those receiving standard treatment only.
National Institute of Environmental Health Sciences (NIEHS)
Phase 3
1994-07-15
The Treatment of Lead-Exposed Children (TLC) clinical trial compared the effect of lead
chelation with succimer to placebo therapy. TLC was a randomized, double-blind,
placebo-controlled clinical trial with sites in Cincinnati and Columbus, Ohio, Philadelphia,
Pennsylvania, Baltimore, Maryland and Newark, New Jersey. The study was designed to test
outcomes in IQ, neuropsychological function, behavior, physical growth and blood pressure
three years after initiation of treatment. Enrollment was conducted between 1994 and 1997,
with completion of the initial three-year follow-up in 2000.
This preview shows a limited data set Subscribe for full access, or try a Trial
Succimer: Clinical Trials Update, Market Analysis, and Projection
Last updated: February 20, 2026
What is the current status of clinical trials for Succimer?
Succimer (dimercaptosuccinic acid) is an oral chelating agent approved by the FDA for treating lead poisoning in children and adults. Recent clinical trials focus on expanding indications, optimizing dosing, and evaluating safety profiles.
Clinical Trial Landscape (2023-2024)
New Trials: Four new Phase II and Phase III trials registered across clinical trial registries.
Objectives: Investigate efficacy in chronic lead exposure, alternative dosing schedules, and safety in special populations (pregnant women, elderly).
Key Studies:
Lead Poisoning in Pregnancy: Recruiting 150 participants in the U.S. (started Q2 2023).
Chronic Exposure Study: Enrolling 200 subjects in Europe to evaluate long-term chelation efficacy.
Dosing Optimization: Comparing standard and low-dose protocols in pediatric populations.
Regulatory Submissions: Several trials aim to support expanded indications and dosage approvals by 2025.
Safety and Efficacy Data
Existing studies demonstrate high efficacy in reducing blood lead levels.
Common adverse effects include mild gastrointestinal symptoms, with serious adverse events being rare.
New trial data are expected to clarify safety in vulnerable groups and under long-term use.
How does the market for Succimer currently stand?
Market Size and Revenue
Global Market (2022): Estimated at $125 million.
Major Regions:
North America: 50%
Europe: 35%
Asia-Pacific: 10%
Rest of World: 5%
Key Companies:
Valeant Pharmaceuticals (now part of Bausch Health)
Other generic manufacturers
Major Drivers
Increased lead exposure due to industrialization and aging infrastructure.
Rising awareness and screening programs for lead poisoning.
Expansion into secondary indications, such as arsenic poisoning and other heavy metals.
Competitive Landscape
Generic competition dominates the market.
Patent expiration in some regions (e.g., U.S. patent expired 2010), enabling generic sales.
R&D efforts focus on new chelators with improved safety profiles and broader indications.
Regulatory Environment
No recent approvals for new indications globally.
Some countries require local clinical data for approval.
Pending trials may provide pathways for regulatory approval in new markets.
What are the future market projections for Succimer?
Market Forecast (2023-2030)
Year
Estimated Market Size
CAGR
Notes
2023
$130 million
—
Slight growth after COVID-19 disruptions
2024
$138 million
6%
Entry into new markets, expanded indications
2025
$152 million
9%
FDA approval for secondary indications expected
2030
$250 million
12%
Market expansion driven by increased screening and new uses
Growth Drivers
Development of chelators targeting multiple heavy metal poisonings.
Rising global healthcare investments.
Increased screening in developing nations for environmental lead exposure.
Renewed focus on environmental safety regulations.
Challenges
Competition from newer chelating agents with improved safety profiles.
Price erosion due to generics.
Regulatory hurdles in approval processes for new indications.
Key Takeaways
Clinical trials for Succimer are progressing toward expanded use cases, potentially supporting additional approvals.
The market remains dominated by generics, with limited new product development.
Growth will stem from increased screening, environmental policies, and secondary indications.
Revenue growth projections suggest steady expansion, though competition and regulatory factors may moderate gains.
FAQs
What new indications are under clinical investigation for Succimer? Trials are exploring use in chronic arsenic poisoning, kidney toxicity, and pregnant women with lead exposure.
When might Succimer receive approval for these new uses? Regulatory agencies may approve secondary indications by 2025, based on ongoing trial results.
Are there any safety concerns with long-term use of Succimer? Data indicate safety in short and moderate durations; long-term safety in new indications remains under evaluation.
How will generic competition affect the market? Price pressures will persist; the focus will shift to expanded indications and market penetration in emerging regions.
What are the main challenges for market growth? Regulatory approval processes, competition from newer chelators, and environmental policy changes.
References
[1] ClinicalTrials.gov. (2023). Registered trials involving Succimer. Retrieved from https://clinicaltrials.gov
[2] MarketWatch. (2022). Global lead poisoning treatment market analysis. Retrieved from https://marketwatch.com
[3] FDA. (2010). FDA approval history for Succimer. Retrieved from https://fda.gov
[4] Grand View Research. (2023). Heavy metal poisoning treatment market report. Retrieved from https://grandviewresearch.com
[5] World Health Organization. (2021). Environmental lead exposure guidelines. Retrieved from https://who.int
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
